Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy BeiGene stock
Learn how to easily invest in BeiGene stock.
BeiGene Ltd is a biotechnology business based in the US. BeiGene shares (BGNE) are listed on the NASDAQ and all prices are listed in US Dollars. BeiGene employs 8,600 staff and has a trailing 12-month revenue of around $1.1 billion.
How to buy shares in BeiGene
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – BGNE – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
BeiGene stock price (NASDAQ: BGNE)Use our graph to track the performance of BGNE stocks over time.
BeiGene shares at a glance
|Latest market close||$136.28|
|52-week range||$118.18 - $392.30|
|50-day moving average||$173.66|
|200-day moving average||$189.41|
|Wall St. target price||$271.64|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-20.05|
Buy BeiGene shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy BeiGene stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
BeiGene price performance over time
|1 week (2022-09-23)||-1.70%|
|1 month (2022-08-30)||-17.67%|
|3 months (2022-06-30)||-15.80%|
|6 months (2022-03-30)||-33.84%|
|1 year (2021-09-30)||-62.46%|
|2 years (2020-09-30)||-52.42%|
|3 years (2019-09-30)||11.29%|
|5 years (2017-09-29)||31.72%|
|Revenue TTM||$1.1 billion|
|Gross profit TTM||$-447,862,000|
|Return on assets TTM||-18.56%|
|Return on equity TTM||-45.01%|
|Market capitalisation||$14.6 billion|
TTM: trailing 12 months
BeiGene share dividends
We're not expecting BeiGene to pay a dividend over the next 12 months.
BeiGene share price volatility
Over the last 12 months, BeiGene's shares have ranged in value from as little as $118.18 up to $392.3. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BeiGene's is 0.6468. This would suggest that BeiGene's shares are less volatile than average (for this exchange).
BeiGene, Ltd. , a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc. , Amgen Inc.
BeiGene in the news
Latest Push by Chinese Firms to Avoid Delistings Falls Short
UK's NICE Recommends BeiGene's Cancer Drug For Rare Form Of Blood Cancer
NICE Recommends BeiGene’s BRUKINSA® (zanubrutinib) for Patients with Waldenström’s Macroglobulinemia who have had at Least One Treatment
Frequently asked questionsWhat percentage of BeiGene is owned by insiders or institutions?
Currently 20.016% of BeiGene shares are held by insiders and 63.386% by institutions. How many people work for BeiGene?
Latest data suggests 8,600 work at BeiGene. When does the fiscal year end for BeiGene?
BeiGene's fiscal year ends in December. Where is BeiGene based?
BeiGene's address is: 55 Cambridge Parkway, Cambridge, MA, United States, 02142 What is BeiGene's ISIN number?
BeiGene's international securities identification number is: US07725L1026 What is BeiGene's CUSIP number?
BeiGene's Committee on Uniform Securities Identification Procedures number is: 07725L102
More guides on Finder
How to buy YanGuFang International Group (YGF) stock when it goes public
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
What are the FAANG stocks and how do you invest in them?
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
How to buy soccer stocks
A simple guide to buying stocks in your favorite European soccer team.
How to buy Juventus stock
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
How to buy AS Roma stock
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
How to buy Borussia Dortmund stock
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
How to buy Lead Real Estate Co. (LRE) stock when it goes public
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
How to buy Third Harmonic Bio (THRD) stock
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
How to buy LINKBANCORP (LNKB) stock
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
Ask an Expert